Rare Genetic Drivers of Lethal Prostate Cancer

Abstract

Genetic testing is a recently adopted standard of care for male patients with metastatic or high-risk localized prostate cancer. 1 Rare deleterious germline alterations in a small number of cancer-associated genes are relevant for clinical management and/or selection of systemic therapy. 2 The most well-known prostate cancer predisposition gene is BRCA2, with deleterious germline BRCA2 variants strongly associated with poor prognosis across the